Table 1.
Demographics and baseline clinical parameters.
| Subject characteristics |
|
Control group, n=72 |
Remote group, n=76 |
P value |
| Male gender, n (%) |
|
54 (75.0) | 55 (72.4) | .72 |
| Age, years |
|
68±9 | 67±10 | .63 |
| Ischemic heart disease, n (%) |
|
32 (44.4) | 39 (51.3) | .40 |
| NYHA functional classification at implant, n (%) |
|
|
|
.59 |
|
|
Class III | 70 (98.5) | 70 (94.5) |
|
|
|
Class IV | 1 (1.4) | 4 (5.4) |
|
| Previous myocardial infarction, n (%) |
|
30 (41.7) | 39 (51.3) | .24 |
| Hypertension, n (%) |
|
27 (37.5) | 30 (39.5) | .81 |
| History of coronary artery intervention, n (%) |
|
21 (29.2) | 22 (29.0) | .98 |
| History of valvular surgery, n (%) |
|
8 (11.1) | 5 (6.6) | .33 |
| Chronic Obstructive Pulmonary Disease (COPD), n (%) |
|
15 (20.8) | 13 (17.0) | .56 |
| AF paroxysmal, n (%) |
|
8 (11.1) | 15 (19.7) | .15 |
| AF persistent, n (%) |
|
1 (1.4) | 4 (5.3) | .37 |
| Implant for primary prevention, n (%) |
|
65 (90.3) | 68 (89.5) | .87 |
| Diabetes, n (%) |
|
23 (32.4) | 26 (35.6) | .68 |
| QRS (ms) |
|
148±30 | 155±25 | .11 |
| LVEF (%) |
|
27±7 | 27±6 | .69 |
| ACE inhibitor or ARB, n (%) |
|
60 (83.3) | 64 (84.2) | .89 |
| ß-blocker, n (%) |
|
63 (87.5) | 66 (86.8) | .91 |
| Diuretic, n (%) |
|
69 (95.8) | 71 (93.4) | .52 |
| Antiarrhythmic agents, n (%) |
|
17 (23.6) | 18 (23.7) | .99 |